Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects

The purpose of this study is the following:

• To evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered tafamidis in Japanese and Western healthy volunteers at single dose.
• To compare Japanese and Western PK profiles.
• Determine the PD stabilization effect of tafamidis on human transthyretin (TTR) in a validated ex vivo assay.

• Drug: Tafamidis meglumin
  
  A single oral dose of 20 mg capsule
  Other Name: PF-06291826
• Drug: Tafamidis meglumin
  
  A single oral dose of 40 mg capsule.
  Other Name: PF-06291826
• Drug: Placebo
  
  A single oral dose of matched placebo.
  Other Name: Not Specified

• Experimental: 20 mg soft gelatin capsule
  
  Intervention: Drug: Tafamidis meglumin
• Experimental: 40 mg (20 mg*2) soft gelatin capsule
  
  Intervention: Drug: Tafamidis meglumin
• Active Comparator: Placebo
  
  Intervention: Drug: Placebo

Inclusion Criteria:

• Healthy male or females.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

Exclusion Criteria:

• Pregnant or nursing females.
• Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception.